News

December 18, 2019

Frontage Holdings Corporation Selected into Hang Seng Hong Kong-Listed Biotech Index

Hang Seng Indexes Company Limited launched the Hang Seng Hong Kong-Listed Biotech Index, the Hang Seng Large-Mid Cap Momentum 50 Index, the Hang Seng Large-Mid Cap Momentum Tilt Index and the Hang Seng Stock Connect Hong Kong Composite Index. Among them, Frontage Holdings Corporation(“Frontage”, 1521.HK), an integrated drug discovery and development contract research organization, was selected into the Hang Seng Hong Kong-Listed Biotech Index and the Hang Seng Stock Connect Hong Kong Composite Index.

The Hang Seng Hong Kong-Listed Biotech Index which includes 39 high-quality biotech stocks, reflects the overall performance of biotech companies that are listed in Hong Kong. In recent years, with growing interest in biotech companies among investors, this new index provides an indicator of the market performance of the sector.

Frontage was listed on the Main Board of the Stock Exchange of Hong Kong on May 30,  2019. It was selected into the Hang Seng Composite SmallCap Index, Hang Seng Healthcare Index, Hang Seng Hong Kong Stock Connect Index, etc. on August 16, 2019, In addition, it was also selected into Hong Kong Stock Connect List on September 9, 2019. The selection into the Hang Seng Hong Kong-Listed Biotech Index and the Hang Seng Stock Connect Hong Kong Composite Index this time shows again the high recognition of the capital market for the company’s business and operations, which will contribute to improvement in the company’s popularity and reputation in Hong Kong’s biotech stocks.

Frontage is a fast-growing contract research organization (“CRO”) providing integrated, science-driven research, analytical and development services throughout the drug discovery and development process to enable pharmaceutical companies to achieve their drug development goals. The Company benefits greatly from having operations in both the United States and China – the two largest markets for CRO services in the world and is well placed to capture growth opportunities in both markets.

The Company believes that a “Two Countries, One System” approach differentiates itself from competitors, as it assures the customers the same quality standards in both China and the United States, while also providing company’s customers with a detailed and highly experienced understanding of the regulations and requirements for drug discovery and development in both countries. The Company positions itself as a value-add partner with a focus on solving customers’ most significant and complex drug discovery and development challenges. The Company’s scientific knowledge base, technical expertise and reputation for high quality services have been integral to its ability to enter into strong long-term strategic relationships and partnerships with the key customers.